✦ LIBER ✦

PP63 Predictive markers in patients with upper gastrointestinal (GI) cancers treated with erlotinib and bevacizumab in a multicenter phase II trial

✍ Scribed by K.S. Rohrberg; I. Buysschaert; H. Pappot; B. Guldhammer Skov; I.J. Christensen; R.K. Olesen; M. Ladekarl; P. Pfeiffer; P. Carmeliet; U. Lassen

Book ID: 119600943
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 45 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(09)72203-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6506 Predictive markers in patients with

6506 Predictive markers in patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab in a multicenter phase II trial

✍ Rohrberg, K.; Pappot, H.; Skov, B.G.; Høyer-Hansen, G.; Christensen, I.J.; Olese 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

P84 Response monitoring with positron em

P84 Response monitoring with positron emission tomography (PET) in patients with advanced non-small-cell lung cancer (NSCLC) treated with bevacizumab and erlotinib: a phase II study

✍ A. de Langen; O. Hoekstra; A. Dingemans; H. Groen; V. van den Boogaart; J. Pruij 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 62 KB

392 POSTER A phase I/II multicenter tria

392 POSTER A phase I/II multicenter trial of BMS-690514, an ErbB-VEGFR inhibitor, in patients with advanced NSCLC who are erlotinib naive or previously treated with erlotinib

✍ J.C. Soria; E. Felip; R. Herbst; N. Hannah; S. laurie; J.P. Armand; F. Shepherd; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Predictive value of serum CA-125 levels

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

✍ Leslie M. Randall; Michael W. Sill; Robert A. Burger; Bradley J. Monk; Barbara B 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 484 KB

A multicenter, Phase II trial of weekly

A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma

✍ Mace L. Rothenberg; John V. Cox; Russell F. DeVore; John D. Hainsworth; Richard 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 2 views

## Background: This multicenter, phase ii trial was performed to evaluate the antitumor activity and toxicity of irinotecan (cpt-11) in patients with metastatic colorectal carcinoma that had recurred or progressed after 5-fluorouracil (5-fu)-based chemotherapy. ## Methods: Cpt-11 was given as a 9

Docetaxel and granulocyte colony-stimula

Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial

✍ K. Alexopoulos; C. Kouroussis; N. Androulakis; E. Papadakis; M. Vaslamatzis; S. 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 90 KB